Company type | Privately held company |
---|---|
Industry | Life Science, Manufacturing |
Founded | 1999 |
Founder | Michael Comb |
Headquarters | Danvers, Massachusetts |
Key people | Michael Comb, President and CEO, Roberto Polakiewicz, CSO, Matthew Curran, CFO, Benjamin Comb, SVP Corporate Strategy, Craig Thompson, VP Global Operations |
Products | Antibodies, ELISA Kits, ChIP Kits, Proteomics kits |
Number of employees | 500 — 550 |
Subsidiaries | Cell Signaling Technology Japan, K.K. Cell Signaling Technology (China) Limited Cell Signaling Technology Europe, B.V. |
Website | www.cellsignal.com |
Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.
Cell Signaling Technology was founded in 1999 by scientists in the Cell Signaling group at New England Biolabs (NEB). [1]
Originally housed in the Cummings Center (Beverly, Massachusetts), CST moved to its current United States headquarters located at the former King’s Grant Inn (Danvers, Massachusetts) in late 2005. [1] [2] Following extensive renovation, [3] the U.S. Green Building Council has certified the current headquarters as a LEED (Leadership in Energy and Environmental Design) certified facility in 2007. [4] In 2008 and 2009, CST expanded its overseas operations, establishing subsidiary offices in the People’s Republic of China, Japan, and the Netherlands. [5] [6]
In 2013, CST moved its production group into an ISO9001 certified facility in Beverly, Massachusetts.
Cell Signaling Technology was named as one of the “Top 100 Places to Work” in a 2009-2013 survey published by the Boston Globe. [7]
In addition to product development and production, CST is also involved in the development of new technologies for signaling analysis as well as mechanistic cell biology research, particularly in the field of cancer research.
CST curates and maintains PhosphoSitePlus, a web-based bioinformatics resource that details post-translational modifications (PTMs) in human, mouse and rat proteins. The types of PTMs curated include phosphorylation, acetylation, methylation, ubiquitylation, glycosylation, etc. This freely accessible, online resource is funded in part through grant support from the NIH, and most recently through the NIH BD2K initiative. [8] [9]
The National Institutes of Health, commonly referred to as NIH, is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through the NIH Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.
In molecular biology, post-translational modification (PTM) is the covalent process of changing proteins following protein biosynthesis. PTMs may involve enzymes or occur spontaneously. Proteins are created by ribosomes, which translate mRNA into polypeptide chains, which may then change to form the mature protein product. PTMs are important components in cell signalling, as for example when prohormones are converted to hormones.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
Leadership in Energy and Environmental Design (LEED) is a green building certification program used worldwide. Developed by the non-profit U.S. Green Building Council (USGBC), it includes a set of rating systems for the design, construction, operation, and maintenance of green buildings, homes, and neighborhoods, which aims to help building owners and operators be environmentally responsible and use resources efficiently.
NetPath is a manually curated resource of human signal transduction pathways. It is a joint effort between Pandey Lab at the Johns Hopkins University and the Institute of Bioinformatics (IOB), Bangalore, India, and is also worked on by other parties.
James Sherley is a biological engineer and the founder of Asymmetrex, an adult stem cell research center. He has also conducted research at the Boston Biomedical Research Institute and Massachusetts Institute of Technology (MIT). Sherley filed a suit against the government in Sherley v. Sebelius, resulting in a protracted legal battle attempting to ban the government from funding any research relating to embryonic stem cells.
Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.
BIOBASE is an international bioinformatics company headquartered in Wolfenbüttel, Germany. The company focuses on the generation, maintenance, and licensing of databases in the field of molecular biology, and their related software platforms.
In historic preservation, sustainable preservation is the idea that preservation has tangible ecological benefits, on the basis that the most sustainable building is one that is already built. Historic buildings can have advantages over new construction with their often central location, historic building materials, and unique characteristics of craftsmanship. Arguing for these connections is at least partially an outgrowth of the green building movement with its emphasis on new construction. Sustainable preservation borrows many of the same principles of sustainable architecture, though is unique by focusing on older buildings versus new construction. The term "sustainable preservation" is also utilized to refer to the preservation of global heritage, archaeological and historic sites through the creation of economically sustainable businesses which support such preservation, such as the Sustainable Preservation Initiative and the Global Heritage Fund.
Utpal Banerjee is a distinguished professor of the department of molecular, cell and developmental biology at UCLA. He obtained his Bachelor of Science degree in chemistry from St. Stephen's College, Delhi University, India and obtained his Master of Science degree in physical chemistry from the Indian Institute of Technology, Kanpur, India. In 1984, he obtained a PhD in chemistry from the California Institute of Technology where he was also a postdoctoral Fellow in the laboratory of Seymour Benzer from 1984-1988.
A biological pathway is a series of interactions among molecules in a cell that leads to a certain product or a change in a cell. Such a pathway can trigger the assembly of new molecules, such as a fat or protein. Pathways can also turn genes on and off, or spur a cell to move. Some of the most common biological pathways are involved in metabolism, the regulation of gene expression and the transmission of signals. Pathways play a key role in advanced studies of genomics.
Michael I. Kotlikoff is an American biomedical researcher, academic leader, and veterinarian who has served as the provost of Cornell University. His work on cardiovascular biology, optogenetics, mouse genetics, and ion channel function has been continuously funded by the National Institutes of Health since 1986. He has served on numerous NIH panels, including chair of the Scientific Board of Councillors of the National Heart, Lung, and Blood Institute (NHLBI) and the NIH Council of Councils, as well as national and international Higher Education committees, including Chair of the Jacobs Technion-Cornell Institute Board and the Advisory Committee for the CityUniversity of Hong Kong Jockey Club College of Veterinary Medicine.
Color Health, Inc. is a population health technology company which provides genetic tests and analysis directly to patients as well as through employers. The product focuses on genes that indicate risk for heart disease, cancer, and that affect medication response.
Chromosome 1 open reading frame 198 (C1orf198) is a protein that in humans is encoded by the C1orf198 gene. This particular gene does not have any paralogs in Homo sapiens, but many orthologs have been found throughout the Eukarya domain. C1orf198 has high levels of expression in all tissues throughout the human body, but is most highly expressed in lung, brain, and spinal cord tissues. Its function is most likely involved in lung development and hypoxia-associated events in the mitochondria, which are major consumers of oxygen in cells and are severely affected by decreases in available cellular oxygen.
Single-pass membrane and coiled-coil domain-containing protein 3 is a protein that is encoded in humans by the SMCO3 gene.
Shelly R. Peyton is an American chemical engineer who is the Armstrong Professional Development Professor in the Department of CHemical Engineering at the University of Massachusetts Amherst. Her research considers the development of biomaterials to investigate metastatic cancer and potential new therapies.
Klarisa Rikova is a senior scientist at Cell Signaling Technology, Inc. (CST) in Danvers, Massachusetts. She has worked at CST since 2000, and worked as a scientist at CST's sister company, Bluefin Biomedicine in Beverly, Massachusetts, from 2015 to 2019.
UBALD1 is a protein encoded by the UBALD1 gene, located on chromosome 16 in humans. UBALD1 has high ubiquitous tissue expression and localizes in the nucleus and cytoplasm. UBALD1 is conserved in animals, including invertebrates. An alias for UBALD1 is FAM100A.